一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

返回ChemicalBook首頁>CAS數(shù)據(jù)庫列表>857402-63-2

857402-63-2

中文名稱 瑞他霉素鹽酸鹽
英文名稱 Retaspimycin Hydrochloride
CAS 857402-63-2
分子式 C31H47N3O8.ClH
分子量 626.186
MOL 文件 857402-63-2.mol
更新日期 2024/11/15 18:20:31
857402-63-2 結(jié)構(gòu)式 857402-63-2 結(jié)構(gòu)式

基本信息

中文別名
瑞他霉素鹽酸鹽
HSP90ATPASE活性抑制劑
英文別名
Ipi-504
Ipi 504
Unii-928Q33Q049
Retaspimycin HCl
IPI-504
IPI504
IPI 504
Retaspimycin hydrochloride
IPI-504 (Retaspimycin HCl)
IPI-504 (RetaspiMycin hydrochloride)
17-Allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride
18,21-Didehydro-17-demethoxy-18,21-dideoxo-18,21-dihydroxy-17-(2-propen-1-ylamino)geldanamycin hydrochloride
所屬類別
生物化工:激動劑抑制劑

物理化學(xué)性質(zhì)

儲存條件-20°C儲存
溶解度≥26.1 mg/mL in DMSO with gentle warming; insoluble in H2O; ≥100 mg/mL in EtOH with ultrasonic
形態(tài)固體
顏色Off-white to pink
瑞他霉素鹽酸鹽價格(試劑級)
報價日期產(chǎn)品編號產(chǎn)品名稱CAS號包裝價格
2026/06/05HY-10210瑞他霉素鹽酸鹽
Retaspimycin Hydrochloride
857402-63-21mg950元
2026/06/05HY-10210瑞他霉素鹽酸鹽
Retaspimycin Hydrochloride
857402-63-25mg1800元
2026/06/05HY-10210瑞他霉素鹽酸鹽
Retaspimycin Hydrochloride
857402-63-210mM * 1mLin DMSO2472元

常見問題列表

生物活性
Retaspimycin Hydrochloride是有效的 Hsp90 抑制劑,EC50 為119 nM。
靶點

HSP90

119 nM (EC 50 )

GRP94

119 nM (EC 50 )

體外研究

Retaspimycin (IPI-504) is a novel and highly soluble analog of 17AAG, an inhibitor of Hsp90. Retaspimycin can abrogate both the unfolded protein response element (UPRE) and ERSE-driven luciferase activity in non-treated U266 and MM.1s cells as well as in Tunicamycin (Tm)-treated cells. The IC 50 s for the inhibition of reporter gene activity by Retaspimycin are 196±56 nM in U266 and 472±177 nM in MM.1s for UPRE-luc activity and 213±140 nM for the ERSE-driven activity in MM.1s cells. Retaspimycin treatment leads to a dose-dependent decrease of p50ATF6 with EC 50 of 237 nM, consistent with the reporter-gene assay. The level of sXBP1 is decreased in the presence of Retaspimycin with an apparent EC 50 between 300 nM and 1 μM. Incubation of Retaspimycin (IPI-504) potently suppresses both Akt and MAPKs phosphorylation in both sensitive and Trastuzumab-resistant cells. Total levels of Akt decreased in all 4 cell lines (BT474, SKBR-3, HCC1569, and HCC1569) in a dose-dependent manner. However, levels of total MAPKs are not significantly altered with Retaspimycin treatment.

體內(nèi)研究

Retaspimycin (IPI-504) and Trastuzumab independently induce tumor regression of Trastuzumab-sensitive BT474 cell-derived xenografts. Xenografts derived from BT474R cells continue to grow in the presence of Trastuzumab but are still sensitive to Retaspimycin. When used in combination, Retaspimycin and Trastuzumab add only marginal benefits to Retaspimycin monotherapy. Retaspimycin (100 mg/kg) as a single agent is more efficacious than Trastuzumab in inhibiting tumor growth in HCC1569 xenografts. The combination is not significantly superior to Retaspimycin used as a single agent.

"857402-63-2" 相關(guān)產(chǎn)品信息
857402-23-4 142-04-1 593-81-7 25606-41-1 590-46-5 593-51-1 506-59-2 554-68-7
建阳市| 宜良县| 吴江市| 武平县| 阿巴嘎旗| 湟中县| 南澳县| 合水县| 吴旗县| 明水县| 麻江县| 洞口县| 西畴县| 确山县| 江西省| 闵行区| 浠水县| 轮台县| 织金县| 丹东市| 文山县| 自治县| 微山县| 通州区| 龙川县| 海兴县| 辉南县| 莲花县| 会昌县| 红原县| 吴旗县| 喀喇| 教育| 鹤岗市| 南城县| 屏南县| 宿迁市| 邵武市| 兴城市| 会理县| 微山县|